Literature DB >> 9373105

Epidemic Bacillus endophthalmitis after cataract surgery I: acute presentation and outcome.

M Roy1, J C Chen, M Miller, D Boyaner, O Kasner, E Edelstein.   

Abstract

OBJECTIVE: The purpose of the study is to report the clinical outcome of acute Bacillus endophthalmitis after cataract surgery.
DESIGN: The study design is a cohort study. PARTICIPANTS: Fourteen eyes of 14 patients with epidemic acute postoperative inflammation after exposure to bacteria-contaminated viscoelastic material were studied. INTERVENTION: Three patients with milder clinical presentations were treated without vitrectomy or antibiotics. Eleven patients with more severe infection were treated with vitrectomy as well as intravitreous and topical fortified antibiotics. MAIN OUTCOME MEASURES: Final visual acuities were obtained in all 14 study patients. Results of microbiologic studies of aqueous and vitreous specimens from 11 vitrectomized eyes also were analyzed.
RESULTS: One patient with late presentation had severe inflammation and had phthisis bulbi develop with no light perception. The remaining 13 patients had successful resolution of inflammation after treatment by 1 month of follow-up. Twelve of these 13 patients, including 1 nonvitrectomized patient, had final visual acuities of 20/100 or better at 6 months' follow-up. Six patients, including two patients with nonvitrectomized eyes, had outcomes of 20/40 or better visual acuity. Bacillus species were grown from all 11 (100%) vitreous and 7 (88%) of 8 aqueous specimens obtained from vitrectomized patients, as well as from the contaminated viscoelastic material remaining in the operating room.
CONCLUSIONS: Postoperative Bacillus endophthalmitis need not result in poor outcome. Results depend on factors including bacterial load, specific bacterial species, timing of treatment, and immune status of the patient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373105     DOI: 10.1016/s0161-6420(97)30028-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Safety of hydroimplantation in cataract surgery in patients with pseudoexfoliation syndrome.

Authors:  Tevfik Oğurel; Reyhan Oğurel; Zafer Onaran; Kemal Örnek
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

2.  The role of pili in Bacillus cereus intraocular infection.

Authors:  Michelle C Callegan; Salai Madhumathi Parkunan; C Blake Randall; Phillip S Coburn; Frederick C Miller; Austin L LaGrow; Roger A Astley; Craig Land; So-Young Oh; Olaf Schneewind
Journal:  Exp Eye Res       Date:  2017-03-20       Impact factor: 3.467

Review 3.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria.

Authors:  Salai Madhumathi Parkunan; C Blake Randall; Phillip S Coburn; Roger A Astley; Rachel L Staats; Michelle C Callegan
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

5.  Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

Authors:  M Kernt; A Kampik
Journal:  Clin Ophthalmol       Date:  2010-03-24

6.  The role of primary needle revision after Ahmed glaucoma valve (AGV) implantation.

Authors:  Maryam Yadgari; Kiana Hassanpour; Fatemeh Vafaei
Journal:  Int Ophthalmol       Date:  2020-08-27       Impact factor: 2.031

7.  CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection.

Authors:  Salai Madhumathi Parkunan; C Blake Randall; Roger A Astley; Glaucia C Furtado; Sergio A Lira; Michelle C Callegan
Journal:  J Leukoc Biol       Date:  2016-06-10       Impact factor: 4.962

8.  Bacillus S-Layer-Mediated Innate Interactions During Endophthalmitis.

Authors:  Md Huzzatul Mursalin; Phillip S Coburn; Erin Livingston; Frederick C Miller; Roger Astley; Ana L Flores-Mireles; Michelle C Callegan
Journal:  Front Immunol       Date:  2020-02-12       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.